In our cohort, TLS incidence following BCMA-targeted CAR-T therapy was 17.1%, indicating that TLS is a relatively common complication in r/r MM treated with CAR-T cells, similar to the previously reported incidence of CD19 CAR-T therapy (4, 16). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.